Literature DB >> 1846923

Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.

W D Kingsbury1, J C Boehm, D R Jakas, K G Holden, S M Hecht, G Gallagher, M J Caranfa, F L McCabe, L F Faucette, R K Johnson.   

Abstract

Water-soluble analogues of the antitumor alkaloid camptothecin (1) were prepared in which aminoalkyl groups were introduced into ring A or B. Most of the analogues were prepared by oxidation of camptothecin to 10-hydroxycamptothecin (2) followed by a Mannich reaction to give N-substituted 9-(aminomethyl)-10-hydroxycamptothecins (4-12) or by subsequent modification of Mannich product 4 (13, 15, 17, 19, 21). Others were obtained by modification of the hydroxyl group of 2 (25,26) or by total synthesis (35,42,43). These analogues, as well as some of their synthetic precursors, were evaluated for inhibition of topoisomerase I, cytotoxicity, and antitumor activity. Although there was not a quantitative correlation between these assays, compounds that inhibited topoisomerase I were also cytotoxic and demonstrated antitumor activity in vivo. Further evaluation of the most active water-soluble analogue led to the selection of 9-[(dimethylamino)methyl]-10-hydroxycamptothecin (4, SK&F 104864) for development as an antitumor agent. In addition to its water solubility, ease of synthesis from natural camptothecin, and high potency, 4 demonstrated broad-spectrum activity in preclinical tumor models and is currently undergoing Phase I clinical trials in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846923     DOI: 10.1021/jm00105a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  58 in total

Review 1.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

2.  MM3(96) parameterization for camptothecin analogs: an ab initio and molecular mechanics study.

Authors:  S W Carrigan; J H Lii; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

3.  Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.

Authors:  S W Carrigan; P C Fox; M E Wall; M C Wani; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

Review 4.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 5.  Anticancer drug discovery and pharmaceutical chemistry: a history.

Authors:  Miguel F Braña; Ana Sánchez-Migallón
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

Review 6.  Natural products as leads to anticancer drugs.

Authors:  M Gordaliza
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

7.  Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.

Authors:  Jessica K Roberts; Anna V Birg; Tong Lin; Vinay M Daryani; John C Panetta; Alberto Broniscer; Giles W Robinson; Amar J Gajjar; Clinton F Stewart
Journal:  Drug Metab Dispos       Date:  2016-04-06       Impact factor: 3.922

Review 8.  Transcription factors as drug targets: opportunities for therapeutic selectivity.

Authors:  T R Butt; S K Karathanasis
Journal:  Gene Expr       Date:  1995

9.  Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model.

Authors:  J Pollina; R J Plunkett; M J Ciesielski; A Lis; T A Barone; S J Greenberg; R A Fenstermaker
Journal:  J Neurooncol       Date:  1998-09       Impact factor: 4.130

10.  Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.

Authors:  R M Scher; R Kosierowski; C Lusch; R Alexander; S Fox; I Redei; F Green; B Raskay; K Amfoh; P F Engstrom; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.